DED: Two Sides of One Disease

Supported by an unrestricted educational grant from Kala Pharmaceuticals

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Describe how DED symptoms can impact patient quality of life.
• Explain how inflammation is a key driver of DED pathogenesis and symptomatology.
• Describe how episodic flares are part of the inflammatory disease process.
• Formulate an individualized treatment plan for patients experiencing DED flares.
• Compare available data on agents in the pipeline and their potential significance for DED management.

Accreditation and Designation Statement

Sponsored by:

Evolve Medical Education LLC (Evolve) is an approved COPE administrator.
This activity, COPE Activity Number 122020, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1 hour CE. 
Course #:  73152-AS
Activity ID: 122020

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Marc Bloomenstein, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, BioTissue, Johnson & Johnson Vision, Kala Pharmaceuticals, Ocusoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, and Sun.

Selina R. McGee, OD, FAAO, Dipl ABO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Cynosure, Dompe, Eyevance, Horizon, Kala Pharmaceuticals, Lumenis, Novartis, Optovue, Versant, and Vertical. Speaker’s Bureau: Allergan, Lumenis, and Optovue.

Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Dompe, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Oyster Point, Pharma, Sun Pharmaceutical Industries, Sight Sciences, and Tarsus. Speaker's Bureau: Allergan, Johnson & Johnson Vision, and Sight Sciences.

The Evolve staff and planners have no financial relationships with commercial interests.
 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Kala Pharmaceuticals.